December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

148.40 UNCHANGED
Delayed Quote Updated: 8:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? ↗
Both of these ETFs look the part, but only one is truly the better buy for investors. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech ↗
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance. 
Via The Motley Fool
Topics ETFs
News headline image
Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals ↗
XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown. 
Via The Motley Fool
Topics ETFs
News headline image
VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗
VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two. 
Via The Motley Fool
Topics ETFs
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
Via The Motley Fool
Topics ETFs World Trade
News headline image
IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy? ↗
XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets? ↗
XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names. 
Via The Motley Fool
Topics ETFs
News headline image
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend. 
Via The Motley Fool
Topics ETFs
News headline image
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite? 
Via The Motley Fool
Topics ETFs
News headline image
Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today ↗
State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 12.55%. Currently, State Street... 
Via Benzinga
Topics ETFs Stocks
News headline image
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗
PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗
One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility. 
Via The Motley Fool
Topics ETFs
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
They have at least one thing in common: An exciting pipeline. 
Via The Motley Fool
Topics ETFs
News headline image
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability. 
Via The Motley Fool
Topics ETFs
News headline image
3 Longevity ETFs to Buy and Hold (and Hold) ↗
The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns. 
Via The Motley Fool
Topics ETFs
News headline image
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗
Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare. 
Via The Motley Fool
Topics ETFs
News headline image
2 Ways to Play the Big Pharma Patent Cliff ↗
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize. 
Via MarketBeat
Topics ETFs Intellectual Property
News headline image
Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge
The small-cap segment of the U.S. stock market has officially entered correction territory, marking a stark reversal for a sector that many analysts expected to lead the "Great Rotation" of 2026. On... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗
Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement. 
Via Stocktwits
Topics ETFs
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon... 
Via Finterra
Topics ETFs Intellectual Property
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day. 
Via Stocktwits
Topics ETFs
News headline image
QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗
Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease... 
Via Stocktwits
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure. 
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
Via Stocktwits
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease. 
Via Stocktwits
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial. 
Via Stocktwits
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 
Via Stocktwits
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.